local_hospital

Umbal - Prof. D-R Stoyan Kirkovich AD

Address
lock Available on a paid plan

Hematology and Blood Disorders

At Umbal - Prof. D-R Stoyan Kirkovich AD, the Department of Clinical Hematology supports a strong portfolio in hemic and lymphatic diseases, with research focused on acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, myelofibrosis, and thrombocytopenia. These studies are designed to test new treatment options, improve disease control, and reduce complications for patients with blood cancers and related disorders.

  • Acute myeloid leukemia and chronic lymphocytic leukemia studies evaluating new cancer therapies
  • Myelofibrosis and polycythemia vera research aimed at improving symptom control and long-term outcomes
  • Immune thrombocytopenia and moderate thrombocytopenia trials assessing better ways to manage low platelet counts
  • Thalassemia studies focused on reducing transfusion burden and supporting blood health

This research area reflects a broad effort to advance care for patients with complex hematologic diseases through more effective and better-tolerated treatment strategies.

Kidney Disease, Metabolism, and Cardiovascular Risk

The site also has active research in nutritional and metabolic diseases, cardiovascular diseases, and pathological conditions, especially chronic kidney disease, proteinuria, heart failure, atherosclerotic cardiovascular disease, and severe hypertriglyceridemia. These trials are generally aimed at slowing disease progression, lowering cardiovascular risk, and improving long-term organ protection.

  • Chronic kidney disease and proteinuria studies exploring better kidney-protective care
  • Heart failure and atherosclerotic cardiovascular disease trials assessing ways to reduce major cardiac events
  • Severe hypertriglyceridemia and obesity research targeting metabolic risk reduction
  • Dialysis-related studies focused on improving outcomes in patients with advanced kidney disease

This area combines kidney, cardiovascular, and metabolic research to help address conditions that often overlap in the same patients.

Autoimmune, Inflammatory, and Skin Diseases

A major part of the research program centers on immune system diseases and skin and connective tissue diseases, including hidradenitis suppurativa, psoriasis, vitiligo, ulcerative colitis, asthma, and chronic urticaria. The purpose of these trials is to evaluate new therapies, maintain disease control over time, and improve symptoms that affect daily life.

  • Hidradenitis suppurativa studies testing new options for a painful chronic skin condition
  • Psoriasis, vitiligo, and psoriatic arthritis research aimed at improving immune-mediated skin and joint disease control
  • Ulcerative colitis trials evaluating treatments for inflammatory bowel disease
  • Chronic inducible urticaria and asthma studies focused on symptom relief and better disease management

These studies show a broad interest in inflammatory disorders where the goal is often to reduce flare-ups, improve comfort, and support longer-term stability.

Liver, Infection, and Respiratory Research

The clinical trial portfolio at Umbal - Prof. D-R Stoyan Kirkovich AD also includes virus diseases, bacterial infections, and respiratory tract diseases, with studies in chronic hepatitis B, chronic hepatitis D, invasive candidiasis, acute bacterial skin infections, and chronic rhinosinusitis without nasal polyps. These trials are mainly aimed at improving infection control, testing antiviral strategies, and easing persistent respiratory symptoms.

  • Chronic hepatitis B and chronic hepatitis D studies exploring new antiviral approaches
  • Invasive candidiasis and bacterial skin infection research assessing better anti-infective treatment options
  • Chronic rhinosinusitis trials focused on reducing ongoing nasal and sinus symptoms
  • Respiratory and infectious disease research supporting improved patient recovery

This work reflects a practical focus on both long-standing viral illness and serious infections, where better treatment choices can make a meaningful difference in outcomes.

Neurology, Psychiatry, and Symptom Management

The site contributes to research in nervous system diseases and mental disorders, including Alzheimer’s disease psychosis, agitation associated with Alzheimer’s dementia, schizophrenia, and bipolar I disorder. In addition, some studies address postoperative pain and other symptom-focused needs, with the overall aim of improving comfort, behavior, and quality of life.

  • Alzheimer’s-related psychosis and agitation trials evaluating ways to better manage difficult neuropsychiatric symptoms
  • Schizophrenia research focused on long-term symptom control and tolerability
  • Bipolar mania studies assessing treatment effectiveness during acute episodes
  • Postoperative pain research aimed at improving short-term pain relief after surgery

This area highlights the site’s interest in both psychiatric care and symptom relief, with studies designed to support patients facing challenging neurological and behavioral conditions.

Site Overview

assignment
89
connected trials
corporate_fare
61
sponsors
science
119
IMPs

Activity Indicator

Last 6 months

6
Trials started
0% vs previous period.
6
Trials started 6–12 months ago
89
Total trials linked
Highly Active
trending_flatStable0%
1
3
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 18 therapeutic areas and 15 of 119 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 115 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
35
Sponsors (total)
61
Active sponsors
28

Sponsor Network

Top 28 by active trials.

lock +27 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +20 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 476 other sites in Bulgaria

description
Trial volume
89
Outperforms 98% of sites
public
Therapeutic diversity
18areas
Outperforms 99% of sites
groups
Sponsor diversity
61sponsors
Outperforms 99% of sites

Therapeutic Area Benchmark — Bulgaria

Select a therapeutic area to compare against other sites in Bulgaria.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Bulgaria

Market Share

Country: Bulgaria

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Umbal - Prof. D-R Stoyan Kirkovich AD

lock Showing 1 of 89 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multicenter, Double-Blind, Randomized Withdrawal Study of Subcutaneous Secukinumab for Long-Term Efficacy and Safety in Moderate to Severe Hidradenitis SuppurativaNovartis Pharma AGPhase IIINot RecruitingMar 2020Jun 2026

IMP list

lock Showing 1 of 119 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide3Unknown2023-06-022025-09-03

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.